Pfizer Inc., of New York, said a study published in the Journal of Clinical Psychiatry showed comparable sexual function in adult patients diagnosed with major depressive disorder (MDD) who were treated daily with Pristiq (desvenlafaxine) extended release tablets at 50 mg and 100 mg doses compared to placebo.